With the increasing momentum and success of monoclonal antibody therapy in conventional
medical practices, there is a revived emphasis on the development of monoclonal …

Background: Hepatitis B virus (HBV) infection remains a global health problem. As “cure” for
chronic hepatitis B is of current priority, hepatitis B immunoglobulin (HBIG) has been utilized …

HBV neutralizing antibodies target the viral envelope antigens (HBsAg) and confer long-
term immune protection in vaccinees and infected humans who seroconvert. They recognize …

The currently available drugs to treat hepatitis B virus (HBV) infection include interferons and
nucleos (t) ide analogs, which can only induce disease remission and are inefficient for the …

Despite the availability of an effective prophylactic vaccine leading to sterilizing immunity,
hepatitis B virus (HBV) is responsible for chronic liver disease in more than 250 million …

Highlights•Neutralizing Abs are generated upon infection but mostly not detectable in
chronic disease.•The B cell response in CHB is altered and critical for disease control.•ICs …

The clinical sequelae associated with chronic HBV infection is generally regarded as a
consequence of an inadequate and inappropriate immune response to active viral …

Chronic hepatitis B is a global public health problem, and coinfection with hepatitis delta
virus (HDV) worsens disease outcome. Here, we describe a hepatitis B virus (HBV) surface …

Introduction: Due to unsatisfactory therapeutic efficacy and considerable side effects of
antiviral drugs in patients with chronic hepatitis B (CHB), immunotherapy has emerged as an …

Chronic hepatitis B (CHB) remains a major public health concern because of the inefficiency
of currently approved therapies in clearing the hepatitis B surface antigen (HBsAg). Antibody …